Pomalidomide-C4-NH2

Background Introduction

Pomalidomide-C4-NH2 is a specialized E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. Combining pomalidomide, a thalidomide analog known for its high binding affinity to the cereblon (CRBN) E3 ubiquitin ligase, with a tailored C4 amine-terminated linker, this compound is optimized for PROTAC (Proteolysis Targeting Chimera) synthesis. The presence of the reactive amine group enables flexible conjugation to a variety of target protein ligands, facilitating the development of novel protein degradation tools and drug discovery processes.

Mechanism

Pomalidomide-C4-NH2 operates as a bifunctional molecule where the pomalidomide moiety binds to the CRBN E3 ubiquitin ligase. The C4 linker provides spatial separation and flexibility, while the terminal NH2 (amine) group serves as a convenient point for covalent attachment to target protein ligands or functional groups. When incorporated into a PROTAC construct, pomalidomide-C4-NH2 binds CRBN, brings it in proximity to the chosen protein of interest, and promotes ubiquitination. This process targets the protein for proteasomal degradation, thereby selectively reducing its levels within the cell.

Applications

Pomalidomide-C4-NH2 is a key building block for the synthesis of CRBN-based PROTACs. Its applications include the development of research tools for targeted protein degradation, validation of new drug targets, and preclinical evaluation of novel therapeutics. This conjugate is widely used by medicinal chemists and researchers designing heterobifunctional degraders for oncology, neurodegenerative disorders, and other disease models. It offers versatility in PROTAC assembly, platform flexibility, and precise control for selective protein knockdown studies in cellular and in vivo contexts.

The Pomalidomide-C4-NH2 E3 Ligase Ligand-Linker Conjugate plays a crucial role in the development of PROTACs, offering a versatile platform for targeted protein degradation. This conjugate features a balanced design that facilitates efficient recruitment of target proteins to the ubiquitin-proteasome system, enhancing the specificity and efficacy of proteolysis-targeting chimeras. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-C4-NH2 is a C4 alkyl chain, imparting moderate flexibility to the molecule. This flexibility allows for optimal spatial orientation between the ligand and the target protein, while its non-cleavable nature ensures stability during the degradation process.

Ligand: The ligand component is derived from pomalidomide, a well-characterized E3 ligase ligand. Its structural features include a glutarimide ring, which is essential for binding to the cereblon E3 ligase, facilitating the recruitment of the target protein for ubiquitination.

Reactive Site: The primary reactive site is the terminal amine group (NH2) of the linker, which is designed to couple with a target protein ligand via amide bond formation. Recommended reaction types include amide coupling reactions, which are efficient and provide stable linkages.

Recommended Target Protein Ligand: The recommended warhead for this conjugate is an electrophilic moiety capable of forming a covalent bond with a nucleophilic site on the target protein. This approach enhances the irreversible binding and degradation of proteins involved in disease pathways, offering significant advantages in therapeutic research and experimental validation.